Primmune Therapeutics, Inc. logo

Primmune Therapeutics, Inc.

Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Primmune is based at JLABS San Diego.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.primmunerx.com
Founded2017
Disease Focus
Development Stage
STOCK CODENon Listed
Address
JLABS San Diego3210 Merryfield Row, CA, 92121
San Diego
United States
Email
Contact Number
+1 888 505 7765

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/primmune-therapeutics” connections=”true” suffix=””]

The TLR7 receptor is expressed on plasmacytoid dendritic cells (pDCs) and B-cells and activation of pDCs produces cytokines and chemokines that up-regulate general cellular responses including NK (natural killer) cell activation, CTL (cytotoxic T-cell or CD8+ T-cell) activation and increase in proliferation and activation of B-cells.